Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ovidiu Chiparus"'
Autor:
Eugene Y. Tan, Ovidiu Chiparus, Somesh Choudhury, Christina Kim, Mike Lau, Christoph Ziltener, Palanichamy Ilankumaran
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(10)
Storage of trametinib tablets outside of 2-8°C protected from moisture may lead to loss of dimethyl sulfoxide (DMSO) and adversely impact trametinib bioavailability. In this open-label, phase 1, single-dose, randomized, 2-treatment, 2-period crossov
Autor:
Jerry Nedelman, Ovidiu Chiparus, Pai-Hsi Huang, Dalila Sellami, Eunju Hurh, Andrew M. Stein, Varun Goel, Jocelyn Zhou, Sven Gogov
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:745-755
Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of sonidegib in healthy subjects and patients with advanced solid tumors was conducted to ch
Publikováno v:
Journal of Polymers and the Environment. 13:107-114
An increasing industrial interest is applications of kenaf and ramie fiber nonwovens for making automotive interior trim parts because of their excellent strength and renewability. This paper presents a study on the manufacture and evaluation of the
Autor:
Andrew M. Stein, Norbert Hollaender, Wenping Wang, Ovidiu Chiparus, Hyewon Kim, Robert J. Motzer, Alison A Carter, C. Sarr
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 311 (2012)
BMC Cancer, Vol 12, Iss 1, p 311 (2012)
Background The phase 3 RECORD-1 trial (NCT00410124) established the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progress on sunitinib or sorafenib. In RECORD-1, patients received 10 mg everolimus dail
Autor:
Frank Giles, Neil Gallagher, Ovidiu Chiparus, Timothy P. Hughes, Ophelia Q. P. Yin, Michele Baccarani, Philipp le Coutre, Hagop M. Kantarjian, Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson
The impact of proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2 blockers) on the efficacy of nilotinib was evaluated. Retrospective analyses were performed in patients with newly diagnosed Philadelphia chromosome-positive (Ph+)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c9f45e26b993973f801092e56e3b21
http://hdl.handle.net/10379/14492
http://hdl.handle.net/10379/14492
Publikováno v:
Journal of Clinical Oncology. 30:2603-2603
2603 Background: Dovitinib is a potent oral inhibitor of Receptor Tyrosine Kinases with activity against FGFR, VEGFR and PDGFR. The objectives of this analysis are to describe the PK/PD of dovitinib to characterize the differences between two differe
Autor:
Norbert Hollaender, C. Sarr, A. Carter, Ovidiu Chiparus, Robert J. Motzer, W. Wang, Andrew M. Stein
Publikováno v:
European Urology Supplements. 10:232